CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction ...

First Lt. Manfredo Martin-Michael Madrigal III photographed as a staff sergeant in 2018. Madrigal pled guilty to making false statements and destroying U.S. Army materials. (Army) A former Army ...

Madrigal Pharma's REZDIFFRA achieved $100-$103M in Q4 sales, marking 61% growth, with market penetration of only 4% relative to TAM, indicating blockbuster potential. Potential competition from ...

Investor expectations may be too high, however. Madrigal unveiled those figures Monday morning. The company said that its preliminary results indicated it earned $100 million to $103 million in ...

Manfredo Martin-Michael Madrigal, 38, was handed a term of four years and six months Thursday during his sentencing in a federal court in Virginia, according to a Justice Department statement the ...

Manfredo Martin-Michael Madrigal, 38, also faced charges stemming from alleged harassment against two former girlfriends who were potential witnesses in the case. In court documents, one woman ...

CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic about the company's sales results. CEO Bill Sibold hailed 2024 as a ...

Manfredo Martin-Michael Madrigal, 38, formerly of Charlottesville, Va., pled guilty in July 2024 to one count of destruction of U.S. Army materials and three counts of making a false statement.

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. The sell-off came after the drugmaker announced its preliminary fourth-quarter and full ...